Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (61-70 of 357) with videos related to

Pageof 36
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Thalidomide in small-cell lung cancer: is it a tombstone?Antonio Rossi, Cesare Gridelli, Emilio Bria
Current Oncology (Toronto, Ont.)|February 23, 2024
The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to PatientsPaolo Maione, Rosario Salvi, Cesare Gridelli
Translational Lung Cancer Research|July 14, 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative reviewAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Switch maintenance versus second-line treatment in non-small cell lung cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Oncology|February 5, 2010
Biological prognostic and predictive factors in lung cancerAntonio Rossi, Domenico Galetta, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Oncology Research|April 3, 2026
Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision MakingPaolo Maione, Valentina Palma, Cesare Gridelli
The New England Journal of Medicine|April 16, 2008
Paclitaxel plus bevacizumab for metastatic breast cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Pageof 36

Showing results (61-70 of 357) with videos related to

Sort By:
Pageof 36
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Thalidomide in small-cell lung cancer: is it a tombstone?Antonio Rossi, Cesare Gridelli, Emilio Bria
Current Oncology (Toronto, Ont.)|February 23, 2024
The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to PatientsPaolo Maione, Rosario Salvi, Cesare Gridelli
Translational Lung Cancer Research|July 14, 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative reviewAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Switch maintenance versus second-line treatment in non-small cell lung cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Oncology|February 5, 2010
Biological prognostic and predictive factors in lung cancerAntonio Rossi, Domenico Galetta, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Oncology Research|April 3, 2026
Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision MakingPaolo Maione, Valentina Palma, Cesare Gridelli
The New England Journal of Medicine|April 16, 2008
Paclitaxel plus bevacizumab for metastatic breast cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Pageof 36